Gitogenin impedes tumorigenesis in hepatocellular carcinoma via NUAK2/NF-κB axis - Takeaways - MDSpire

Gitogenin impedes tumorigenesis in hepatocellular carcinoma via NUAK2/NF-κB axis

  • By

  • Xiaomei Bao

  • Yiman Liu

  • Hua Sheng

  • Qingge Dai

  • Lingjuan Sun

  • Ye Zhang

  • Yuehong Ma

  • Yu Dong

  • June 24, 2026

  • 0 min

Share

  • 1

    Gitogenin (Gito) inhibits hepatocellular carcinoma (HCC) growth by promoting autophagy and inhibiting epithelial-mesenchymal transition (EMT).

  • 2

    Gito's anti-HCC effects are mediated through the NUAK2/NF-κB signaling pathway, which it blocks to suppress tumor progression.

  • 3

    In vitro and in vivo experiments demonstrated that Gito reduces HCC cell invasion and migration.

  • 4

    Overexpression of NUAK2 diminishes the inhibitory effects of Gito on HCC cells, indicating its role in tumor development.

  • 5

    This study suggests that Gito may serve as a potential therapeutic agent targeting NUAK2 in HCC treatment.

Original Source(s)

Gitogenin impedes tumorigenesis in hepatocellular carcinoma via NUAK2/NF-κB axis

  • by Xiaomei Bao, Yiman Liu, Hua Sheng, Qingge Dai, Lingjuan Sun, Ye Zhang, Yuehong Ma, Yu Dong

  • June 24, 2026

Related Content

Radiomics-based interpretable machine learning model from multiphasic CT imaging for predicting pathological grade in upper tract urothelial carcinoma: a multicenter study

Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report

Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy